Suzanne B. Hendrix
Suzanne B. Hendrix publishes mostly in Psychiatry and Mental health, Physiology and Pharmacology, on topics such as Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments and Cholinesterase and Neurodegenerative Diseases.
- World rank
- #607,228 of 7,710,434 ranked researchers
- Rank in United States
- #208,076 of 1,627,098
- Works
- 275
- Citations
- 5.9k
- Citations per work
- 21.4
What does Suzanne B. Hendrix research?
Suzanne B. Hendrix's work is mostly in Medicine (44%), Mathematics (7%), Economics, Econometrics and Finance (7%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences12043.7%
- Medicine12043.7%
- Everything else11541.7%
- Physical Sciences207.3%
- Mathematics207.3%
- Social Sciences207.3%
- 1Psychiatry and Mental health18% of their works
- 2Physiology12% of their works
- 3Pharmacology8% of their works
- 4Statistics and Probability7% of their works
- 5Economics and Econometrics7% of their works
- 6Neurology6% of their works
Research topics
- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Cholinesterase and Neurodegenerative Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Statistical Methods in Clinical Trials
- Amyotrophic Lateral Sclerosis Research
- Computational Drug Discovery Methods
- Neurological Disorders and Treatments
Which keywords describe Suzanne B. Hendrix's research?
The keywords of their largest research topics: Alzheimer's Disease, Biomarkers, Dementia, Mild Cognitive Impairment, Neurodegeneration, Oxidative Stress, Amyloid Hypothesis and Tau Pathology.
- Citicoline
- Virtual Screening
- TDP-43
- False Discovery Rate
- Quality of Life
- Cholinesterase Inhibitors
- Tau Pathology
- Oxidative Stress
- Mild Cognitive Impairment
- Biomarkers
- Alzheimer's Disease
- Dementia
- Neurodegeneration
- Amyloid Hypothesis
- Acetylcholinesterase
- Cost-effectiveness Analysis
- Adaptive Designs
- FUS/TLS
- Molecular Docking
- Cerebrolysin
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 20 words, with their numbers
- Alzheimer's Disease1583 topics
- Biomarkers1272 topics
- Dementia1001 topic
- Mild Cognitive Impairment1001 topic
- Neurodegeneration782 topics
- Oxidative Stress762 topics
- Amyloid Hypothesis641 topic
- Tau Pathology641 topic
- Acetylcholinesterase461 topic
- Cholinesterase Inhibitors461 topic
- Cost-effectiveness Analysis411 topic
- Quality of Life411 topic
- Adaptive Designs271 topic
- False Discovery Rate271 topic
- FUS/TLS141 topic
- TDP-43141 topic
- Molecular Docking131 topic
- Virtual Screening131 topic
- Cerebrolysin121 topic
- Citicoline121 topic
Where does Suzanne B. Hendrix work?
Suzanne B. Hendrix's main affiliation in the publication record is TetraLogic Pharmaceuticals (United States), United States.
How many publications and citations does Suzanne B. Hendrix have?
OpenAlex counts 275 works and 5,873 citations for Suzanne B. Hendrix, an h-index of 39, ranking #607,228 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Suzanne B. Hendrix. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.